Valuation: TScan Therapeutics, Inc.

Market Cap 69.27M 60.59M 55.89M 51.62M 97.94M 6.61B 99.59M 668M 262M 3.25B 260M 254M 11.19B P/E 2026 *
-1.21x
P/E 2027 * -1.15x
Enterprise Value -29.6M -25.89M -23.88M -22.05M -41.85M -2.82B -42.55M -285M -112M -1.39B -111M -109M -4.78B EV / Sales 2026 *
-3.92x
EV / Sales 2027 * -0.7x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-18 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-06 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+2.36%
1 week+3.81%
Current month+11.21%
1 month+18.67%
3 months+3.81%
6 months-6.84%
Current year+9.00%
1 week 1.01
Extreme 1.01
1.28
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Director of Finance/CFO 57 28/01/2024
Chief Tech/Sci/R&D Officer 50 07/04/2024
Director TitleAgeSince
Director/Board Member 68 22/03/2021
Director/Board Member 56 23/05/2023
Chairman 55 11/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

67,000 0.1200%
05-19Free

Director

67,000 0.1200%
05-19Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+2.36%+3.81%-40.76%-49.54% 69.27M
-4.14%-7.44%+64.26%+119.36% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.59%+2.93%+18.78%+462.79% 25.63B
-1.55%-2.49%-19.60%-14.74% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.64%+2.09%+25.50%+197.27% 14.35B
Average -0.40%+1.05%+45.63%+125.83% 24.23B
Weighted average by Cap. -1.06%+0.29%+56.55%+138.17%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.1M 5.63M 10.69M 721M 10.87M 72.85M 28.61M 355M 28.38M 27.76M 1.22B 7.81M 6.83M 6.3M 5.82M 11.04M 745M 11.22M 75.26M 29.55M 367M 29.31M 28.68M 1.26B
Net income -115M -101M -92.84M -85.75M -163M -10.97B -165M -1.11B -436M -5.41B -432M -423M -18.59B -125M -109M -101M -93.01M -176M -11.9B -179M -1.2B -473M -5.86B -469M -458M -20.16B
Net Debt -98.87M -86.48M -79.77M -73.67M -140M -9.43B -142M -953M -374M -4.65B -371M -363M -15.97B -74.76M -65.39M -60.31M -55.71M -106M -7.13B -107M -721M -283M -3.51B -281M -275M -12.07B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
10/07/26 US$1.085 +2.36% 916,176
09/07/26 US$1.060 -15.87% 1,266,274
08/07/26 US$1.260 +17.76% 2,637,071
07/07/26 US$1.070 +1.90% 606,643
06/07/26 US$1.050 -0.94% 418,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.060USD
Average target price
6.000USD
Spread / Average Target
+466.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock